Entezarian Maryam, Ameli Fereshteh, Masir Noraidah, Chin Tan Geok
Department of Pathology, Faculty of Medicine, University Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
Department of Pathology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Science, Iran.
Iran J Pathol. 2022 Spring;17(2):202-209. doi: 10.30699/IJP.2022.540192.2740. Epub 2022 Mar 8.
BACKGROUND & OBJECTIVE: Ovarian cancer is associated with the highest mortality rate among gynecologic malignancies. Despite new therapeutic strategies, ovarian cancer still has a high risk of metastasis and mortality. Endocan is a newly identified endothelial cell activation marker, which is responsible for angiogenesis, tumor invasion, and aggressive behavior of tumors. The aim of this study was to assess Endocan expression in different types of ovarian tumors and to identify its relationship with clinicopathologic characteristics of ovarian tumors.
This cross-sectional study was conducted on 183 tissue samples, including benign, borderline, and malignant ovarian tumors collected from the University Kebangsaan Malaysia Medical Center archive of Pathology during 2005-2015. Mouse monoclonal anti-human Endocan/ESM-1 Clone MEP08 was used at a dilution of 1:400 for immunohistochemical (IHC) staining. All the information was collected by a checklist, and the association between clinicopathological features and high or low levels of Endocan -MVD was evaluated using Pearson chi-square, Fischer's exact, or Monte Carlo tests.
The prevalence of Endocan positivity was significantly higher in malignant compared to borderline and benign ovarian tumors (<0.001). There was also a significant association between type of tumor and Endocan status in malignant ovarian tumors (=0.02), indicating that Endocan positivity was more likely in serous malignant ovarian tumors compared to other ovarian tumor types. However, the tumor stage was not significantly associated with Endocan status (=0.31).
This study showed that Endocan positivity may show the highest prevalence among malignant tumors suggesting that high Endocan expression would be negatively associated with ovarian tumor behavior.
卵巢癌是妇科恶性肿瘤中死亡率最高的。尽管有新的治疗策略,但卵巢癌仍有很高的转移和死亡风险。内皮糖蛋白是一种新发现的内皮细胞激活标志物,与血管生成、肿瘤侵袭及肿瘤的侵袭性行为有关。本研究旨在评估内皮糖蛋白在不同类型卵巢肿瘤中的表达,并确定其与卵巢肿瘤临床病理特征的关系。
本横断面研究对183份组织样本进行,这些样本包括2005年至2015年期间从马来西亚国民大学医学中心病理档案中收集的良性、交界性和恶性卵巢肿瘤。小鼠单克隆抗人内皮糖蛋白/内皮细胞特异性分子-1克隆MEP08以1:400的稀释度用于免疫组织化学(IHC)染色。所有信息通过检查表收集,使用Pearson卡方检验、Fisher精确检验或蒙特卡罗检验评估临床病理特征与内皮糖蛋白-微血管密度高低水平之间的关联。
与交界性和良性卵巢肿瘤相比,恶性卵巢肿瘤中内皮糖蛋白阳性的患病率显著更高(<0.001)。在恶性卵巢肿瘤中,肿瘤类型与内皮糖蛋白状态之间也存在显著关联(=0.02),表明与其他卵巢肿瘤类型相比,浆液性恶性卵巢肿瘤中内皮糖蛋白阳性的可能性更大。然而,肿瘤分期与内皮糖蛋白状态无显著关联(=0.31)。
本研究表明,内皮糖蛋白阳性在恶性肿瘤中的患病率可能最高,提示内皮糖蛋白高表达与卵巢肿瘤行为呈负相关。